Executive Summary
The evolution of precision oncology has largely been defined by increasingly selective therapeutic strategies. Molecularly targeted agents transformed cancer treatment by exploiting specific biological vulnerabilities, while antibody-drug conjugates (ADCs) extended this principle by coupling tumor recognition with delivery of potent cytotoxic payloads. These advances established an important premise: the clinical value of an anticancer agent depends not only on its intrinsic activity, but also on the ability to concentrate pharmacologic exposure within malignant tissue while limiting exposure to normal tissue.
As precision oncology has matured, however, an important distinction has emerged: molecular specificity does not necessarily translate into a sufficiently wide therapeutic index. This distinction is increasingly apparent in the rapidly expanding ADC field. Sleuth’s Q3 2026 analysis describes approximately 2,045 ADC programs, including roughly 440 clinical-stage programs. Despite the breadth of this activity, development remains concentrated around a comparatively limited group of validated targets, while differentiation is increasingly shifting toward payload, linker, conjugation chemistry, and molecular architecture. More importantly, the report identifies therapeutic window as a central determinant of combination potential and predicts that future value creation in next-generation ADCs will increasingly reward improvements in therapeutic index rather than target novelty alone.
Macrocycle Drug Conjugates (MDCs) represent a distinct approach to this challenge. Rather than relying upon antibody-mediated recognition of a specific cell-surface antigen, MDCs are designed to use macrocyclic molecular architecture to influence tumor distribution, cellular uptake, retention, and payload exposure. NOVO-111, INNOVOTEX’s lead MDC candidate, applies this strategy to oxaliplatin, an established platinum agent whose utility in gastrointestinal oncology is substantial but whose cumulative toxicity can constrain treatment. The development thesis is straightforward: the therapeutic mechanism does not necessarily need to be reinvented if its therapeutic index can instead be re-engineered.
NOVO-111: Engineering the Pharmacology of Oxaliplatin
NOVO-111 is INNOVOTEX’s lead application of the MDC platform and is being developed to determine whether macrocycle-mediated delivery can improve the therapeutic index of platinum chemotherapy. The construct incorporates an oxaliplatin-derived platinum component within a texaphyrin-based macrocyclic architecture intended to alter the distribution and retention of platinum relative to conventional oxaliplatin.
The development thesis is deliberately grounded in validated biology. NOVO-111 is not intended to introduce a fundamentally new mechanism of tumor killing. Instead, it seeks to preserve the therapeutic value of platinum-mediated cytotoxicity while modifying the pharmacologic environment in which that activity occurs. In this respect, NOVO-111 represents an effort to redesign exposure rather than reinvent mechanism.
INNOVOTEX’s preclinical program has evaluated whether this architecture can increase tumor associated platinum exposure relative to conventional oxaliplatin and whether altered distribution can translate into antitumor activity at tolerated exposures. The company’s preclinical findings support continued investigation of this hypothesis, but remain preclinical and therefore cannot establish clinical superiority or predict the magnitude of a therapeutic-index advantage in humans.
Mice were evaluated in a 28 day GLP-like safety study evaluating NOVO-111 in comparison to oxaliplatin. Abbreviated results are provided above illustrating well tolerated doses of NOVO-111 over the course of the 14 day treatment window. These results are in stark contrast to oxaliplatin, which killed 40% of mice at equivalent does to that of NOVO-111. These results illustrate the enhanced tolerability of NOVO-111 as a macrocycle drug conjugate containing a prodrug of oxaliplatin.
The next generation of precision oncology may therefore be defined not only by the discovery of new biological targets, but by increasingly sophisticated control over therapeutic exposure. The opportunity is not simply to discover what to target, but to engineer what happens after the drug arrives.